Print




ESTRO-ESSO-ESMO Evidence and New Challenges in Rectal Cancer

7 - 10 October 2012, Madrid, Spain


Faculty

Course Director:

Vincenzo Valentini, Radiotion Oncologist, Universita Cattolica S. Cuore, Rome (IT)

Teachers:
Regina Beets-Tan, Radiologist, University Hospital Maastricht (NL)
Joseph M. Borras, Epidemiologist, Cancer Plan, Department of Health, L'Hospitalet de Llobregat, Barcelona (ES)
Claudio Coco, Surgeon, Università Cattolica S.Cuore, Rome (IT)
Karin Haustermans, Radiation Oncologist, University Hospital Gasthuisberg, KU-Leuven (BE)
Corrie Marijnen, Radiation Oncologist, Nederlands Kanker Instituut, Amsterdam (NL)
Lars Pahlman, Surgeon, Uppsalal University Hospital (SE)
Claus Rödel, Radiation Oncologist, University Hospital Erlangen (DE)
Hans-Joachim Schmoll, Medical Oncologist, Martin Luther University Halle-Wittenberg (DE)
Nigel Scott, Pathologist, St James' University Hospital, Leeds (GB)
Cornelis Van De Velde, Surgeon, Leiden University Medical Center (NL)


Aim of the course

This course, jointly organized by ESTRO, ESSO and ESMO seeks to promote an integrated approach between all specialists involved in rectal cancer to tailor the best treatment for each individual patient. The most relevant ongoing questions in multidisciplinary management of rectal cancer patients will be addressed in open debates and interaction with experts. In a truly multidisciplinary atmosphere, you will be able to identify the major uncertainties of your daily practice and learn how to handle them. You will have the opportunity to design a new research, starting from available state of the art evidences.The presence of colleagues with different specialties, from all over the world, will enrich your perspective and your daily practice. Don't miss this chance to encounter the best science in rectal cancer patients' management.

Target Group

The target group consists of surgeons, radiotherapists and medicals oncologists involved in the multidisciplinary treatment of rectal cancer.

Educational Programme

Day 1

  • What we consider state of art in rectal cancer by ESSO, ESMO, and ESTRO
- Epidemiology of rectal cancer in Europe
- For surgery
- For radiotherapy
- For chemotherapy
  • The house believes that mesorectal fascia involvement requires tailored treatment:
Case presentation
- Is tumor penetration more dangerous than nodal involvement?
- Is quality of surgery more relevant than stage?
- Can radio(chemo-)therapy modify surgical margins?

Case Discussion
- Workshops

Day 2

  • The house believes that nodal status is not detectable by imaging:
Case presenation
- Is nodal involvement location a prognostic factor?
- Is nodal involvement detectable by imaging?
- Does nodal status change radiotherapy strategy?

Case discussion
- Workshops

  • The house believes that laparoscopy surgery is a new gold standard:
Case presenation
- Does open surgery see the nerves easily?
- Does laparoscopy surgery handle the tumour extension properly?
- Do evidences support laparoscopy surgery right now?

Case discussion
- Workshops
  • The house believes no surgery in responders patients is reliable: case presentation & case discussion

Case presenation
- Are the data from Brazil enough?
- Is a local excision necessary?
- Is brachytherapy an option for these patients?

Case discussion

Day 3

  • Workshops

  • The house believes that (neo) adjuvant therapy options can be adapted to the response along the treatment course:

Case presentation
- Is pre-operative MRI as a prognostic/ predictive marker in rectal cancer?
- Can we manage a risk based choice for (neo)adjuvant treatment ?
- How can we optimize timing, lasting, and drug choice for chemotherapy?

Case dicussion

  • The house believes that synchronous metastatic patients can be cured:
Case presentation
- What is the role and optimal timing of chemo?
- What is the role and optimal timing of surgery?
- What is the role and optimal timing of RT?

Case discussion
- Working group on ‘New proposal for randomized studies’

Day 4

  • The house believes that population based data are more relevant than randomized studies:
Case presentation
- The epidemiology evidences
- The Scandinavian approach
- The EURECCA perspective

Case discussion
- General debate on ‘New proposal for randomized studies

Course Venue
Meliá Galgos
Calle de Claudio Coello,
139 28006, Madrid – Spain
Tel: +34 91 5626600
www.meliagalgos.com


Practical Organisation
Please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Regsitration
Participants should register online at: www.estro.org - Education
If online registration is not possible please contact:
ESTRO OFFICE • Av. E. Mounierlaan 83/12 • B-1200 Brussels
Tel.: +32 2 775 93 39 • Fax: +32 2 779 54 94
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it


Regsitration fees

Up to 09/07/12 inclusive                   After 09/07/12
Technologist members       450 €               625 €
Junior members                 450 €              625 €
Members                          600 €              725 €
Non members                   750 €               850 €

The fee includes the course material, coffees, lunches, and the social event.


ESTRO GOES GREEN - Please note that the course material is now distributed onsite on a USB stick. No printed course book will be provided during the courses.

Advanced registation and payment is required. Onsite registration will not be available

To view the course flyer

 


< Prev   Next >